The plasma protease C1-inhibitor treatment market consists of drugs used for treating angioedema, a hereditary disorder caused due to deficiency or dysfunction of C1-inhibitor protein in the blood. These treatments aim to replace or supplement low levels of C1-inhibitor to reduce swelling caused by angioedema attacks. Some key products in this market include Cinryze, Haegarda and Takhzyro. With increasing awareness about rare disease management and availability of targeted therapies, demand for plasma protease C1-inhibitor treatments is growing.

The Global plasma protease C1-inhibitor treatment Market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the plasma protease C1-inhibitor treatment are R&D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble. These companies are focusing on expanding their product portfolios as well as global footprint to leverage new opportunities arising from growing diagnosis and treatment rates.

The Plasma Protease C1-Inhibitor Treatment Market Size is witnessing several opportunities such as rise in incidence of hereditary angioedema, development of subcutaneous C1-inhibitor formulations, and availability of customized treatment plans. This is encouraging new players to enter the market and existing ones to enhance research activities.

Major companies in this market are engaged in expanding their global presence through organic and inorganic growth strategies. For instance, in 2021, Takeda Pharmaceuticals acquired Shire to become a global biopharmaceutical leader. Similarly, CSL Behring established new plasma collection centers in the U.S. to meet rising protein therapies demand. These expansions will help companies cater to diverse patient needs worldwide.

Market drivers:

- Rising prevalence of hereditary angioedema (HAE): Increasing incidence of HAE globally due to improved diagnosis is a major market driver. It is estimated that 1 in 10,000-50,000 people worldwide have HAE.

Market restraints:

- High costs associated with targeted therapies: C1-inhibitor replacement therapies are expensive costing between US$ 100,000-200,000 annually creating affordability issues. This hinders widespread adoption, especially in low-income countries.

Segment Analysis
The plasma protease C1-inhibitor treatment market is dominated by the hereditary angioedema (HAE) segment. HAE is a rare genetic disorder where C1-inhibitor (C1-INH) protein - which controls inflammation and regulates activation of other proteins - is deficient or functions improperly. Patients suffer from unpredictable and painful swelling in various body parts including abdomen, face, limbs and throat. C1-INH replacement therapy using plasma derived or recombinant C1-INH products are the standard preventive treatment options for HAE patients to manage acute swelling attacks and is the largest revenue generating segment in this market.

Global Analysis
North America holds the largest share in the plasma protease C1-inhibitor treatment market due to increasing awareness regarding hereditary angioedema treatment options and established healthcare infrastructure in the region. However, Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to rising healthcare expenditure, large patient pool and growing presence of key biopharmaceutical companies focusing on expanding their operations in emerging Asian countries.

Get more insights on This Topic- Plasma Protease C1-Inhibitor Treatment Market